William Blair Reiterates Outperform Rating on Exelixis (EXEL), 'First pivotal success from the zanzalintinib program'
Tweet Send to a Friend
William Blair analyst Andy Hsieh reiterated an Outperform rating on Exelixis (NASDAQ: EXEL)The analyst commented, "Sunday’s announcement represents the first ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
